Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines
Author:
Filipić Brankica1, Pantelić Ivana2ORCID, Nikolić Ines23ORCID, Majhen Dragomira4ORCID, Stojić-Vukanić Zorica1, Savić Snežana2ORCID, Krajišnik Danina2ORCID
Affiliation:
1. Department of Microbiology and Immunology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia 2. Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, 11000 Belgrade, Serbia 3. Section of Pharmaceutical Sciences, University of Geneva, 1206 Geneva, Switzerland 4. Division of Molecular Biology, Ruđer Bošković Institute, 10000 Zagreb, Croatia
Abstract
Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms that induce a broader immune response compared to traditional vaccines. Modern vaccines tend to rely on certain nanotechnology platforms but are still expected to be readily available and easy for large-scale manufacturing and to induce a durable immune response. In this review, we present an overview of the most promising nanoadjuvants and nanoparticulate delivery systems and discuss their benefits from tehchnological and immunological standpoints as well as their objective drawbacks and possible side effects. The presented nano alums, silica and clay nanoparticles, nanoemulsions, adenoviral-vectored systems, adeno-associated viral vectors, vesicular stomatitis viral vectors, lentiviral vectors, virus-like particles (including bacteriophage-based ones) and virosomes indicate that vaccine developers can now choose different adjuvants and/or delivery systems as per the requirement, specific to combatting different infectious diseases.
Funder
Ministry of Science, Technological Development and Innovation, Republic of Serbia through a Grant Agreement with University of Belgrade, Faculty of Pharmacy Croatian Science Foundation COST Action CA16231 European Network of Vaccine Adjuvants
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference172 articles.
1. Lemoine, C., Thakur, A., Krajišnik, D., Guyon, R., Longet, S., Razim, A., Górska, S., Pantelic, I., Ilic, T., and Nikolic, I. (2020). Technological Approaches for Improving Vaccination Compliance and Coverage. Vaccines, 8. 2. Recent Patents on Nasal Vaccines Containing Nanoadjuvants;Candela;Recent. Adv. Drug. Deliv.,2022 3. From vaccines to nanovaccines: A promising strategy to revolutionize rheumatoid arthritis treatment;Zhang;J. Control. Release,2022 4. Delivering more for less: Nanosized, minimal-carrier and pharmacoactive drug delivery systems;Etter;Adv. Drug. Deliv. Rev.,2021 5. Yuba, E., Kado, Y., Kasho, N., and Harada, A. (J. Control. Release, 2022). Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines, J. Control. Release, Online ahead of print.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|